Goodpasture syndrome secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(9 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
{{Goodpasture syndrome}}
{{CMG}}; {{AE}}{{Akshun}}


{{Goodpastures syndrome}}
==Overview==
Effective measures for the [[secondary prevention]] of Goodpasture syndrome include patient education. Patients should be educated about the signs and symptoms of [[renal]] dysfunction as certain [[steroid]] and [[immunosuppressive]] therapy may have adverse effects on the [[kidneys]]. Patients should be monitored regularly for [[renal function]] and those with severe dysfunction should have be referred for [[dialysis]].
 
==Secondary Prevention==
Effective measures for the secondary prevention of Goodpasture syndrome include:<ref name="pmid10541306">{{cite journal |vauthors=Kluth DC, Rees AJ |title=Anti-glomerular basement membrane disease |journal=J. Am. Soc. Nephrol. |volume=10 |issue=11 |pages=2446–53 |date=November 1999 |pmid=10541306 |doi= |url=}}</ref><ref name="pmid25553369">{{cite journal| author=Menn-Josephy H, Beck LH| title=Recurrent glomerular disease in the kidney allograft. | journal=Front Biosci (Elite Ed) | year= 2015 | volume= 7 | issue=  | pages= 135-48 | pmid=25553369 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25553369  }} </ref><ref name="pmid25028634">{{cite journal| author=| title=Notice. | journal=Kidney Int Suppl (2011) | year= 2012 | volume= 2 | issue= 2 | pages= 139 | pmid=25028634 | doi=10.1038/kisup.2012.9 | pmc=4089568 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25028634  }} </ref><ref name="pmid20924413">{{cite journal| author=Chen M, Kallenberg CG| title=ANCA-associated vasculitides--advances in pathogenesis and treatment. | journal=Nat Rev Rheumatol | year= 2010 | volume= 6 | issue= 11 | pages= 653-64 | pmid=20924413 | doi=10.1038/nrrheum.2010.158 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20924413  }} </ref>
 
*Patient education: [[Patient education]] is an important aspect in early diagnosis and management of Goodpasture syndrome.
**Patients with [[lung]] involvement should be strictly advised against [[smoking]] to prevent recurrent [[pulmonary hemorrhage]].
**Patients should be educated about the signs and symptoms of [[renal dysfunction]] as certain [[steroid]] and [[Immunosuppressive therapy|immunosuppressive]] therapy may have adverse effects on the [[kidneys]].
**Patients should be monitored regularly for [[renal function]] and dose adjustment of medications.
**Patients with severe [[renal dysfunction]] require long term [[dialysis]] and should be advised to seek [[medical care]] on a timely basis.
**Patients with deteriorating renal function despite maximal medical therapy should be put on [[renal transplantation]] list and patients should be informed that Goodpasture syndrome may even recur in the transplanted kidney, although it is very rare.


==References==
==References==
Line 14: Line 26:
[[Category:Pulmonology]]
[[Category:Pulmonology]]
[[Category:Needs content]]
[[Category:Needs content]]
[[Category:Disease]]

Latest revision as of 15:17, 1 May 2018

Goodpasture syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Goodpasture syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Goodpasture syndrome secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Goodpasture syndrome secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Goodpasture syndrome secondary prevention

CDC on Goodpasture syndrome secondary prevention

Goodpasture syndrome secondary prevention in the news

Blogs on Goodpasture syndrome secondary prevention

Directions to Hospitals Treating Goodpasture syndrome

Risk calculators and risk factors for Goodpasture syndrome secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Effective measures for the secondary prevention of Goodpasture syndrome include patient education. Patients should be educated about the signs and symptoms of renal dysfunction as certain steroid and immunosuppressive therapy may have adverse effects on the kidneys. Patients should be monitored regularly for renal function and those with severe dysfunction should have be referred for dialysis.

Secondary Prevention

Effective measures for the secondary prevention of Goodpasture syndrome include:[1][2][3][4]

  • Patient education: Patient education is an important aspect in early diagnosis and management of Goodpasture syndrome.

References

  1. Kluth DC, Rees AJ (November 1999). "Anti-glomerular basement membrane disease". J. Am. Soc. Nephrol. 10 (11): 2446–53. PMID 10541306.
  2. Menn-Josephy H, Beck LH (2015). "Recurrent glomerular disease in the kidney allograft". Front Biosci (Elite Ed). 7: 135–48. PMID 25553369.
  3. "Notice". Kidney Int Suppl (2011). 2 (2): 139. 2012. doi:10.1038/kisup.2012.9. PMC 4089568. PMID 25028634.
  4. Chen M, Kallenberg CG (2010). "ANCA-associated vasculitides--advances in pathogenesis and treatment". Nat Rev Rheumatol. 6 (11): 653–64. doi:10.1038/nrrheum.2010.158. PMID 20924413.

Template:WH Template:WS